MCID: FLL027
MIFTS: 62

Fallopian Tube Carcinoma

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Carcinoma

MalaCards integrated aliases for Fallopian Tube Carcinoma:

Name: Fallopian Tube Carcinoma 12 51 14 69
Fallopian Tube Cancer 12 49 36 51 14
Cancer of the Fallopian Tube 12 49
Neoplasm of Fallopian Tube 12 28
Fallopian Tube Neoplasms 41 69
Malignant Neoplasm of Fallopian Tube 69
Malignant Neoplasm of Uterine Tube 12
Malignant Tumour of Fallopian Tube 12
Malignant Tumor of Fallopian Tubes 55
Malignant Tumor of Fallopian Tube 12
Tumor, Fallopian Tube, Malignant 12
Carcinoma of Fallopian Tube 12
Tumor of the Fallopian Tube 12
Cancer of Fallopian Tubes 55
Fallopian Tube Neoplasm 12
Malignant Tubal Tumor 55
Fallopian Tube Ca 12
Tubal Cancer 55

Characteristics:

Orphanet epidemiological data:

55
malignant tumor of fallopian tubes
Prevalence: 1-9/100000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:1963 DOID:1964
MeSH 41 D005185
ICD10 32 C57.0
ICD9CM 34 183.2
Orphanet 55 ORPHA180242
UMLS via Orphanet 70 C0153579 C0238122
ICD10 via Orphanet 33 C57.0
KEGG 36 H01554

Summaries for Fallopian Tube Carcinoma

NIH Rare Diseases : 49 Fallopian tube cancer develops in the tubes that connect a woman's ovaries and uterus. It is very rare and accounts for only 1-2% of all gynecologic cancers.  Fallopian tube cancer occurs when normal cells in one or both tubes change and grow in an uncontrolled way, forming a mass called a tumor. Cancer can begin in any of the different cell types that make up the fallopian tubes. The most common type is called adenocarcinoma (a cancer of cells from glands). Leiomyosarcoma (a cancer of smooth muscle cells) and transitional cell carcinoma (a cancer of the cells lining the fallopian tubes) are more rare.  While some fallopian tube cancers actually begin in the tubes themselves, fallopian tube cancer is more often the result of cancer spreading from other parts of the body to the tubes. For example, the fallopian tubes are a common site of metastasis (spread) of cancers that started in the ovaries, uterus, endometrium, (the tissue lining the uterus) appendix, or colon.  Women with fallopian tube cancer may experience symptoms, although some affected women may have no symptoms at all. The signs of fallopian tube cancer are often non-specific, meaning that they can also be signs of other medical conditions that are not cancer. Signs and symptoms of fallopian tube cancer can include: irregular or heavy vaginal bleeding (especially after menopause); occasional abdominal or pelvic pain or feeling of pressure; vaginal discharge that may be clear, white, or tinged with blood; and a pelvic mass or lump. Doctors use many tests to diagnose cancer of the fallopian tubes. Some of these tests may include: pelvic examination, transvaginal ultrasound, a blood test that measures the tumor marker CA-125, computed tomography (CT or CAT) scan, and magnetic resonance imaging (MRI). Fallopian tube cancer can be best treated when detected early. If the cancer has spread to the walls of the tubes or outside of the tubes, then there is a lower chance that the disease can be treated successfully. The stage of the cancer determines the type of treatment needed. Most women will need surgery and some will go on to have chemotherapy and/or radiation therapy. Last updated: 5/6/2015

MalaCards based summary : Fallopian Tube Carcinoma, also known as fallopian tube cancer, is related to fallopian tube adenocarcinoma and tuberculous salpingitis. An important gene associated with Fallopian Tube Carcinoma is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Olaparib and Poly(ADP-ribose) Polymerase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include fallopian tube, ovary and testes, and related phenotypes are Increased cell death HMECs cells and Synthetic lethal with cisplatin

Disease Ontology : 12 A female reproductive organ cancer that is located in fallopian tube.

Wikipedia : 72 Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates... more...

Related Diseases for Fallopian Tube Carcinoma

Diseases related to Fallopian Tube Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 fallopian tube adenocarcinoma 31.6 BRCA1 BRCA2 ERBB2 TP53
2 tuberculous salpingitis 30.3 BRCA1 BRCA2 ERBB2
3 uterine carcinosarcoma 30.1 ERBB2 PGR TP53
4 familiar fallopian tube carcinoma 12.1
5 fallopian tube carcinosarcoma 11.1
6 glioma susceptibility 1 10.5 ERBB2 TP53
7 non-proliferative fibrocystic change of the breast 10.4 ERBB2 TP53
8 endometrium carcinoma in situ 10.4 PGR TP53
9 pleomorphic adenoma carcinoma 10.4 ERBB2 TP53
10 scirrhous adenocarcinoma 10.4 ERBB2 PGR
11 breast apocrine carcinoma 10.4 ERBB2 PGR
12 oral leukoplakia 10.4 ERBB2 TP53
13 female reproductive endometrioid cancer 10.4 PGR TP53
14 breast malignant phyllodes tumor 10.4 PGR TP53
15 olfactory groove meningioma 10.4 PGR TP53
16 intracystic papillary adenoma 10.4 ERBB2 PGR
17 progesterone-receptor negative breast cancer 10.4 ERBB2 PGR
18 chordoid glioma 10.4 PGR TP53
19 esophagus adenocarcinoma 10.4 ERBB2 TP53
20 tetraploidy 10.4 BRCA2 TP53
21 hereditary site-specific ovarian cancer syndrome 10.4 BRCA1 BRCA2
22 anterior cranial fossa meningioma 10.4 PGR TP53
23 brca1 hereditary breast and ovarian cancer syndrome 10.4 BRCA1 BRCA2
24 breast squamous cell carcinoma 10.4 ERBB2 PGR
25 breast reconstruction 10.3 BRCA1 BRCA2
26 breast-ovarian cancer, familial 1 10.3 BRCA1 BRCA2
27 granulosa cell tumor of the ovary 10.3 ERBB2 TP53
28 lynch syndrome i 10.3 BRCA1 BRCA2
29 myxosarcoma 10.3 BRCA1 TP53
30 peritoneum cancer 10.3 BRCA1 BRCA2
31 premature menopause 10.3 BRCA1 BRCA2
32 endometrial clear cell adenocarcinoma 10.3 ESR1 TP53
33 breast secretory carcinoma 10.3 ERBB2 PGR
34 clear cell adenofibroma 10.3 BRCA1 BRCA2
35 gastric lymphoma 10.3 TP53 VEGFA
36 soft tissue sarcoma 10.2 TP53 VEGFA
37 pancreatic serous cystadenoma 10.2 PGR VEGFA
38 cystadenofibroma 10.2 BRCA1 BRCA2
39 comedo carcinoma 10.2 ERBB2 ESR1
40 vulvar syringoma 10.2 ESR1 PGR
41 lung leiomyoma 10.2 ESR1 PGR
42 vulvar benign neoplasm 10.2 ESR1 PGR
43 trigonitis 10.2 ESR1 PGR
44 vulvar leiomyoma 10.2 ESR1 PGR
45 uterine body mixed cancer 10.2 ERBB2 PGR TP53
46 microglandular adenosis 10.2 ERBB2 PGR TP53
47 predominantly cortical thymoma 10.2 ESR1 PGR
48 progesterone resistance 10.2 ESR1 PGR
49 cribriform carcinoma 10.2 ESR1 PGR
50 angiomatous meningioma 10.2 PGR VEGFA

Comorbidity relations with Fallopian Tube Carcinoma via Phenotypic Disease Network (PDN):


Ovarian Cancer

Graphical network of the top 20 diseases related to Fallopian Tube Carcinoma:



Diseases related to Fallopian Tube Carcinoma

Symptoms & Phenotypes for Fallopian Tube Carcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.26 BRCA1 MYC PGR TP53
2 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Fallopian Tube Carcinoma:

43 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.19 BRCA2 BRCA1 ERBB2 TP53 VEGFA ESR1
2 cellular MP:0005384 10.18 BRCA2 BRCA1 ERBB2 VEGFA TP53 MYC
3 embryo MP:0005380 10.16 BRCA1 ERBB2 BRCA2 ESR1 VEGFA PGR
4 endocrine/exocrine gland MP:0005379 10.15 BRCA1 ERBB2 BRCA2 TP53 VEGFA ESR1
5 cardiovascular system MP:0005385 10.13 BRCA1 ERBB2 VEGFA TP53 MYC ESR1
6 homeostasis/metabolism MP:0005376 10.13 BRCA2 BRCA1 ERBB2 VEGFA TP53 MYC
7 digestive/alimentary MP:0005381 10.11 BRCA2 BRCA1 ERBB2 TP53 VEGFA ESR1
8 integument MP:0010771 10.1 BRCA1 ERBB2 BRCA2 ESR1 VEGFA TP53
9 hematopoietic system MP:0005397 10.08 BRCA2 BRCA1 VEGFA TP53 MYC ESR1
10 limbs/digits/tail MP:0005371 10.08 BRCA1 ERBB2 BRCA2 ESR1 VEGFA PGR
11 mortality/aging MP:0010768 10.06 BRCA2 BRCA1 ERBB2 VEGFA TP53 MYC
12 immune system MP:0005387 10.05 BRCA2 BRCA1 VEGFA TP53 MYC ESR1
13 neoplasm MP:0002006 10.01 BRCA1 ERBB2 BRCA2 ESR1 VEGFA PGR
14 muscle MP:0005369 9.98 BRCA1 ERBB2 TP53 VEGFA ESR1 PGR
15 nervous system MP:0003631 9.91 BRCA2 BRCA1 ERBB2 VEGFA TP53 MYC
16 normal MP:0002873 9.86 BRCA1 ERBB2 BRCA2 TP53 VEGFA ESR1
17 reproductive system MP:0005389 9.76 BRCA1 ERBB2 BRCA2 TP53 VEGFA ESR1
18 no phenotypic analysis MP:0003012 9.72 VEGFA TP53 MYC ESR1 PGR
19 respiratory system MP:0005388 9.35 BRCA1 ERBB2 VEGFA TP53 ESR1
20 skeleton MP:0005390 9.23 BRCA1 ERBB2 BRCA2 TP53 VEGFA ESR1

Drugs & Therapeutics for Fallopian Tube Carcinoma

Drugs for Fallopian Tube Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 356)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1 763113-22-0 23725625
2 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
6
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Epirubicin Approved Phase 3 56420-45-2 41867
14
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
15
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
18
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
19
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
20
Rucaparib Approved, Investigational Phase 3,Phase 2,Phase 1 283173-50-2 9931954
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
22
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
24
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
25
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
26
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
27
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1 56-86-0 33032
28
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
29
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475
30
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
31
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
32
Trebananib Investigational Phase 3,Phase 2,Phase 1 894356-79-7
33
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
34 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
35
Fosbretabulin Investigational Phase 2, Phase 3 222030-63-9 5351387
36
Maleic acid Experimental Phase 2, Phase 3, Phase 1 110-16-7 444266
37 Combretastatin Investigational Phase 2, Phase 3 82855-09-2
38 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
39 Antimitotic Agents Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
41 Alkylating Agents Phase 2, Phase 3, Phase 1
42 Isophosphamide mustard Phase 2, Phase 3 0
43 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
44 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
45 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
46 Antibodies Phase 3,Phase 2,Phase 1
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1
48 Antimetabolites Phase 3,Phase 2,Phase 1
49 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
50 Antiviral Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 577)

# Name Status NCT ID Phase Drugs
1 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
2 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
3 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
4 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
5 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
6 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
7 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
8 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
10 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
11 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3 TCG;TC
12 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
13 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
14 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
15 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
16 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
17 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
18 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
19 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
20 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
21 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
22 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
23 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
24 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
25 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
26 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
27 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
28 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
29 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
30 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
31 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
32 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
33 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
34 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
35 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
36 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
37 PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Recruiting NCT02631876 Phase 3 IMGN853;Paclitaxel;Doxorubicin;Topotecan
38 Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 Recruiting NCT02903004 Phase 3 Trabectedin;Pegylated Liposomal Doxorubicin;Topotecan;Gemcitabine;Weekly Paclitaxel;Carboplatin
39 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
40 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Recruiting NCT02328716 Phase 3 Hipec with Cisplatin
41 Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
42 A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. Recruiting NCT03106987 Phase 3 Active Comparator: Olaparib tablets;Placebo
43 Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients Recruiting NCT03402841 Phase 3 Olaparib
44 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
45 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) Recruiting NCT02859038 Phase 3
46 Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) Recruiting NCT02718417 Phase 3 carboplatin;paclitaxel;Avelumab;Avelumab
47 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
48 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
49 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting NCT02032823 Phase 3 Olaparib;Placebo
50 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel

Search NIH Clinical Center for Fallopian Tube Carcinoma

Cochrane evidence based reviews: fallopian tube neoplasms

Genetic Tests for Fallopian Tube Carcinoma

Genetic tests related to Fallopian Tube Carcinoma:

# Genetic test Affiliating Genes
1 Neoplasm of Fallopian Tube 28

Anatomical Context for Fallopian Tube Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Fallopian Tube Carcinoma:

18
Fallopian Tube

MalaCards organs/tissues related to Fallopian Tube Carcinoma:

38
Ovary, Testes, T Cells, Appendix, Uterus, Smooth Muscle, Colon

Publications for Fallopian Tube Carcinoma

Articles related to Fallopian Tube Carcinoma:

(show all 50)
# Title Authors Year
1
Successful diagnosis of an occult fallopian tube carcinoma detected from the diaphragm metastasis. ( 29327265 )
2018
2
Skin metastases in epithelial ovarian and fallopian tube carcinoma. ( 28816970 )
2017
3
Triple Synchronous Malignancies in Genital Tract; Primary Endometrial, Ovarian and Fallopian Tube Carcinoma: A Case Report. ( 28274004 )
2017
4
Evaluation of Short-Term Efficacy of Concurrent Chemoradiotherapy in Primary Fallopian Tube Carcinoma by Diffusion-Weighted Imaging: A Retrospective Study. ( 28423375 )
2017
5
Primary Fallopian Tube Carcinoma: A Case Report and Literature Review. ( 28698755 )
2017
6
Identifying features of primary fallopian tube carcinoma using magnetic resonance imaging. ( 28721103 )
2017
7
Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study. ( 26825825 )
2016
8
Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma. ( 27307153 )
2016
9
Comment on Shama Chaudhry et al (J Pak Med Assoc 2016; 66: 107-110) Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 27122289 )
2016
10
Response to comment on Shama Chaudhry et al (J Pak Med Assoc 2016; 66: 107-110) Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 27122290 )
2016
11
Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 26712194 )
2016
12
Associations of Promoter Methylations and mRNA Expressions of MMP-2, MMP-7 and MMP-9 with Primary Fallopian Tube Carcinoma. ( 26785083 )
2016
13
Comparison of survival outcome of patients with primary peritoneal and fallopian tube carcinoma treated with neoadjuvant chemotherapy versus primary debulking surgery. ( 27976970 )
2016
14
Prognostic Significance of Retroperitoneal Lymphadenectomy, Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Primary Fallopian Tube Carcinoma: A Multicenter Study. ( 25622588 )
2015
15
Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma. ( 25846583 )
2015
16
Magnetic resonance imaging features of fallopian tube carcinoma. ( 25890392 )
2015
17
Robotic resection of bulky aorto-caval lymphadenopathy in a patient with serous fallopian tube carcinoma. ( 25449567 )
2015
18
Primary fallopian tube carcinoma: review of MR imaging findings. ( 26150249 )
2015
19
Metastatic fallopian tube carcinoma presenting as an inguinal hernia. ( 25675933 )
2015
20
Primary fallopian tube carcinoma--a retrospective analysis of 66 cases. ( 26050354 )
2015
21
Clinically Occult Primary Fallopian Tube Carcinoma Presenting as a Malignant Pleural Effusion. ( 26646473 )
2015
22
Primary fallopian tube carcinoma: correlation between magnetic resonance and diffuse weighted imaging characteristics and histopathologic findings. ( 25373473 )
2015
23
Genomic aberrations of BRCA1-mutated fallopian tube carcinomas. ( 24726640 )
2014
24
Co-existence of primary fallopian tube carcinoma and uterine carcinosarcoma. ( 24912001 )
2014
25
Primary fallopian tube carcinoma diagnosed with endoscopic ultrasound elastography with fine needle biopsy. ( 25325010 )
2014
26
Clinical and survival analysis of 36 cases of primary fallopian tube carcinoma. ( 25307473 )
2014
27
Primary fallopian tube carcinoma: a case report and mini-review of the literature. ( 25507436 )
2014
28
Primary fallopian tube carcinoma: a case report. ( 25426210 )
2014
29
Primary fallopian tube carcinoma: a case report and mini-review of the literature. ( 25423713 )
2014
30
Primary fallopian tube carcinoma diagnosed preoperatively by cervical smear. ( 25827704 )
2014
31
Primary fallopian tube carcinoma and ectopic pregnancy: A rare co-occurrence. ( 24411050 )
2013
32
Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features. ( 22038216 )
2011
33
Uncommon manifestations of Endocervical Malignant Mixed Mullerian Tumor with Incidental Bilateral Fallopian Tube Carcinoma. ( 21701666 )
2011
34
Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. ( 19898224 )
2009
35
Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. ( 19761129 )
2009
36
Expression of insulin-like growth factor-1 receptors, Wilm's tumor-1 protein, c-kit and p16 in primary fallopian tube carcinoma in diabetic patients. ( 17972088 )
2008
37
Microinvasive fimbrial fallopian tube carcinoma in a BRCA-2 mutation carrier. ( 18207147 )
2008
38
HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. ( 17927588 )
2007
39
Fallopian tube carcinoma: incidental finding during surgery for acute pelvic inflammatory disease--case report. ( 17139993 )
2006
40
BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? ( 16319259 )
2005
41
Management of bilateral fallopian tube carcinoma coexistent with tuberculous salpingitis. ( 15669995 )
2005
42
Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. ( 15252324 )
2004
43
Tuberculous salpingitis in two of five primary fallopian tube carcinomas. ( 12745571 )
2003
44
Incidental diagnosis of primary fallopian tube carcinoma during prophylactic salpingo-oophorectomy in BRCA2 mutation carrier. ( 12504983 )
2002
45
Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. ( 10629373 )
2000
46
Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. ( 10785486 )
2000
47
Recurrent fallopian tube carcinoma: TP53 mutation and clinical course. ( 10782411 )
2000
48
c-erbB-2 and p53 expression in fallopian tube carcinoma. ( 7773939 )
1995
49
Primary fallopian tube carcinoma with coexistent tuberculous salpingitis: a case report. ( 1556508 )
1992
50
Exfoliative dermatitis: presenting sign of fallopian tube carcinoma. ( 2967452 )
1988

Variations for Fallopian Tube Carcinoma

Cosmic variations for Fallopian Tube Carcinoma:

9 (show top 50) (show all 94)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10648 TP53 endometrium,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 6
2 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 6
3 COSM10656 TP53 endometrium,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 6
4 COSM43596 TP53 endometrium,NS,carcinoma,adenocarcinoma c.841G>A p.D281N 6
5 COSM10659 TP53 endometrium,NS,carcinoma,adenocarcinoma c.817C>T p.R273C 6
6 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 6
7 COSM10709 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 6
8 COSM44063 TP53 endometrium,NS,carcinoma,adenocarcinoma c.389T>G p.L130R 6
9 COSM10704 TP53 endometrium,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 6
10 COSM11073 TP53 endometrium,NS,carcinoma,adenocarcinoma c.1024C>T p.R342* 6
11 COSM44622 TP53 endometrium,NS,carcinoma,adenocarcinoma c.694A>G p.I232V 6
12 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 6
13 COSM10654 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 6
14 COSM45035 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 6
15 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 6
16 COSM43545 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 6
17 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 6
18 COSM6932 TP53 endometrium,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 6
19 COSM10863 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.833C>T p.P278L 6
20 COSM43955 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.514G>A p.V172I 6
21 COSM10794 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.796G>A p.G266R 6
22 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 6
23 COSM14050 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1516G>A p.V506M 6
24 COSM14049 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1067C>T p.P356L 6
25 COSM5215 PTEN endometrium,NS,carcinoma,adenocarcinoma c.356T>A p.V119D 6
26 COSM5154 PTEN endometrium,NS,carcinoma,adenocarcinoma c.697C>T p.R233* 6
27 COSM5107 PTEN endometrium,NS,carcinoma,adenocarcinoma c.71A>G p.D24G 6
28 COSM5216 PTEN endometrium,NS,carcinoma,adenocarcinoma c.389G>T p.R130L 6
29 COSM5235 PTEN endometrium,NS,carcinoma,adenocarcinoma c.218A>T p.E73V 6
30 COSM5299 PTEN endometrium,NS,carcinoma,adenocarcinoma c.271G>T p.E91* 6
31 COSM5152 PTEN endometrium,NS,carcinoma,adenocarcinoma c.388C>T p.R130* 6
32 COSM5236 PTEN endometrium,NS,carcinoma,adenocarcinoma c.275A>T p.D92V 6
33 COSM5219 PTEN endometrium,NS,carcinoma,adenocarcinoma c.388C>G p.R130G 6
34 COSM5312 PTEN endometrium,NS,carcinoma,adenocarcinoma c.895G>T p.E299* 6
35 COSM5106 PTEN endometrium,NS,carcinoma,adenocarcinoma c.335T>C p.L112P 6
36 COSM5065 PTEN endometrium,NS,carcinoma,adenocarcinoma c.403A>G p.I135V 6
37 COSM5039 PTEN endometrium,NS,carcinoma,adenocarcinoma c.518G>A p.R173H 6
38 COSM5048 PTEN endometrium,NS,carcinoma,adenocarcinoma c.196A>G p.K66E 6
39 COSM5159 PTEN endometrium,NS,carcinoma,adenocarcinoma c.733C>T p.Q245* 6
40 COSM5115 PTEN endometrium,NS,carcinoma,adenocarcinoma c.155A>G p.D52G 6
41 COSM5033 PTEN endometrium,NS,carcinoma,adenocarcinoma c.389G>A p.R130Q 6
42 COSM5943 PTEN endometrium,NS,carcinoma,adenocarcinoma c.634+3A>C p.? 6
43 COSM5276 PTEN endometrium,NS,carcinoma,adenocarcinoma c.386G>T p.G129V 6
44 COSM5105 PTEN endometrium,NS,carcinoma,adenocarcinoma c.284C>T p.P95L 6
45 COSM5212 PTEN endometrium,NS,carcinoma,adenocarcinoma c.319G>T p.D107Y 6
46 COSM5108 PTEN endometrium,NS,carcinoma,adenocarcinoma c.209T>C p.L70P 6
47 COSM5165 PTEN endometrium,NS,carcinoma,adenocarcinoma c.519C>T p.R173R 6
48 COSM937333 POLE endometrium,NS,carcinoma,adenocarcinoma c.857C>G p.P286R 6
49 COSM5031089 POLE endometrium,NS,carcinoma,adenocarcinoma c.890C>A p.S297Y 6
50 COSM937331 POLE endometrium,NS,carcinoma,adenocarcinoma c.890C>T p.S297F 6

Expression for Fallopian Tube Carcinoma

Search GEO for disease gene expression data for Fallopian Tube Carcinoma.

Pathways for Fallopian Tube Carcinoma

Pathways related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 BRCA1 ERBB2 ESR1 MYC TP53 VEGFA
2
Show member pathways
13.56 BRCA1 ERBB2 ESR1 MYC PGR PSMB4
3
Show member pathways
13.54 BRCA1 BRCA2 ERBB2 ESR1 MYC TP53
4
Show member pathways
13.37 BRCA1 ERBB2 MYC PSMB4 TP53 VEGFA
5
Show member pathways
13.27 BRCA1 BRCA2 MYC PSMB4 TP53
6
Show member pathways
13.19 ERBB2 MYC PSMB4 TP53 VEGFA
7
Show member pathways
12.87 BRCA1 BRCA2 ERBB2 MYC TP53 VEGFA
8
Show member pathways
12.82 BRCA1 MYC TP53 VEGFA
9
Show member pathways
12.7 BRCA1 ESR1 MYC PSMB4 TP53
10 12.63 BRCA2 ERBB2 ESR1 MYC TP53 VEGFA
11
Show member pathways
12.46 ERBB2 ESR1 TP53 VEGFA
12
Show member pathways
12.37 ERBB2 MYC TP53
13 12.37 BRCA1 ERBB2 MYC TP53 VEGFA
14
Show member pathways
12.36 ERBB2 MYC TP53 VEGFA
15
Show member pathways
12.28 BRCA1 ESR1 VEGFA
16
Show member pathways
12.24 BRCA1 MYC TP53
17
Show member pathways
12.24 BRCA1 BRCA2 ESR1 MYC PSMB4 TP53
18
Show member pathways
12.17 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
19
Show member pathways
12.12 BRCA1 PSMB4 TP53
20
Show member pathways
12.09 BRCA1 ESR1 MYC PGR
21 12.07 ERBB2 ESR1 MYC TP53 VEGFA
22 12.06 MYC TP53 VEGFA
23 11.93 PSMB4 TP53 VEGFA
24 11.89 ESR1 MYC TP53
25 11.88 ERBB2 MYC TP53
26 11.88 MYC TP53 VEGFA
27
Show member pathways
11.85 ERBB2 ESR1 PGR
28
Show member pathways
11.84 BRCA2 ERBB2 MYC TP53 VEGFA
29
Show member pathways
11.75 ERBB2 ESR1 MYC VEGFA
30
Show member pathways
11.72 BRCA1 BRCA2 TP53
31 11.66 BRCA1 ERBB2 TP53
32 11.62 ERBB2 MYC TP53 VEGFA
33 11.59 ERBB2 MYC TP53
34 11.56 BRCA1 ERBB2 MYC
35 11.52 BRCA1 ERBB2 MYC TP53
36 11.45 ESR1 MYC VEGFA
37 11.41 BRCA1 MYC TP53
38 11.39 BRCA1 MYC TP53
39 11.36 ESR1 MYC TP53
40 11.33 BRCA1 MYC TP53 VEGFA
41 11.29 BRCA1 BRCA2 ESR1 MYC TP53 VEGFA
42 11.28 ESR1 TP53
43 11.28 TP53 VEGFA
44 11.28 BRCA2 ESR1 MYC
45 11.25 ESR1 TP53
46 11.22 MYC TP53
47 11.2 BRCA1 TP53
48 11.18 BRCA1 TP53
49 11.15 BRCA1 TP53
50 11.13 ESR1 MYC

GO Terms for Fallopian Tube Carcinoma

Cellular components related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.8 BRCA1 BRCA2 ESR1 MYC PGR PSMB4
2 cytoplasm GO:0005737 9.61 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
3 nuclear chromatin GO:0000790 9.5 ESR1 MYC TP53
4 lateral element GO:0000800 9.16 BRCA1 BRCA2
5 protein complex GO:0043234 9.02 BRCA1 BRCA2 ESR1 MYC TP53

Biological processes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.92 BRCA1 ESR1 MYC TP53
2 cellular response to DNA damage stimulus GO:0006974 9.85 BRCA1 BRCA2 MYC TP53
3 positive regulation of transcription, DNA-templated GO:0045893 9.85 BRCA1 BRCA2 ESR1 MYC TP53
4 cell proliferation GO:0008283 9.8 BRCA2 ERBB2 MYC TP53
5 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 BRCA1 ESR1 MYC PGR TP53 VEGFA
6 regulation of transcription by RNA polymerase II GO:0006357 9.77 BRCA1 ERBB2 ESR1 MYC VEGFA
7 negative regulation of gene expression GO:0010629 9.71 ESR1 MYC PGR VEGFA
8 cellular response to hypoxia GO:0071456 9.69 MYC TP53 VEGFA
9 positive regulation of epithelial cell proliferation GO:0050679 9.65 ERBB2 MYC VEGFA
10 DNA synthesis involved in DNA repair GO:0000731 9.63 BRCA1 BRCA2
11 negative regulation of fibroblast proliferation GO:0048147 9.62 MYC TP53
12 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.61 BRCA2 TP53
13 cell aging GO:0007569 9.61 BRCA2 TP53
14 chromosome organization GO:0051276 9.6 BRCA2 MYC
15 positive regulation of mesenchymal cell proliferation GO:0002053 9.59 MYC VEGFA
16 positive regulation of cell cycle arrest GO:0071158 9.58 BRCA1 TP53
17 strand displacement GO:0000732 9.58 BRCA1 BRCA2
18 response to X-ray GO:0010165 9.57 BRCA2 TP53
19 mammary gland alveolus development GO:0060749 9.56 ESR1 VEGFA
20 positive regulation of gene expression GO:0010628 9.55 BRCA1 ERBB2 MYC TP53 VEGFA
21 positive regulation of leukocyte migration GO:0002687 9.54 TP53 VEGFA
22 cellular response to estrogen stimulus GO:0071391 9.52 ESR1 MYC
23 chordate embryonic development GO:0043009 9.43 BRCA1 BRCA2
24 response to gamma radiation GO:0010332 9.43 BRCA2 MYC TP53
25 protein deubiquitination GO:0016579 9.35 BRCA1 ESR1 MYC PSMB4 TP53
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53
27 transcription, DNA-templated GO:0006351 10.1 BRCA1 ERBB2 ESR1 MYC PGR TP53

Molecular functions related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.8 BRCA1 BRCA2 ESR1 MYC PGR TP53
2 sequence-specific DNA binding GO:0043565 9.67 ESR1 MYC PGR TP53
3 protein heterodimerization activity GO:0046982 9.46 ERBB2 MYC TP53 VEGFA
4 protein C-terminus binding GO:0008022 9.43 BRCA2 ERBB2 TP53
5 steroid binding GO:0005496 9.4 ESR1 PGR
6 enzyme binding GO:0019899 9.26 BRCA1 ESR1 PGR TP53
7 identical protein binding GO:0042802 9.1 BRCA2 ERBB2 ESR1 PGR TP53 VEGFA

Sources for Fallopian Tube Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....